Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on November 12, 2014, reporting events that occurred on November 11, 2014. The filing announces the release of financial results for the quarter ended September 30, 2014, and a subsequent management conference call.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and conference call script (Exhibit 99.2) referenced in the report but are not detailed in the body of this Form 8-K.
Material Changes
No specific material changes versus the prior comparable period are quantified in this document. The filing serves solely as a notification that the quarterly results have been announced and the supporting documents have been furnished.
Guidance, Outlook, and Risks
Management held a conference call to discuss earnings and operating results, but the specific guidance, outlook, or risk commentary is not included in the text of this filing. The document explicitly states that the information in the attached exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Zafgen, Inc., as the input metadata incorrectly listed Larimar Therapeutics, Inc.
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for the quarter ended September 30, 2014.
- Review Exhibit 99.2 (Conference Call Script) for management's specific commentary on future guidance and operational risks.
- Confirm the filing date of November 12, 2014, and the event date of November 11, 2014.